PYXS News and Press, Pyxis Oncology Inc. From 03/25/25

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy ...

2025-03-19 00:56:21 ET More on Pyxis Oncology Pyxis Oncology rises on FDA fast track tag for lead asset Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earnings data for Pyxis Oncology Financial information for Pyxis Oncology Read t...

- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) - ...

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat ...

2025-03-01 14:28:42 ET More on iShares Biotechnology ETF, SPDR S&P Biotech ETF, etc. XBI: Diverse Holding Amid Strong Catalysts, Buy 2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone iShares Biotechnology ETF: Playing Defense ...

2025-02-26 07:55:47 ET Shares of Pyxis Oncology ( NASDAQ: PYXS ) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and neck cancer.... Read the full article on See...

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201 for the tr...

- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial expanded to include cohorts in recurrent/metastatic head and n...